Department of Surgery, University of Chicago Pritzker Medical School, MC 5095, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
World J Surg. 2011 Jul;35(7):1500-4. doi: 10.1007/s00268-011-1031-9.
The surgical and medical management of inflammatory bowel disease (IBD) has significantly evolved over the course of the last two decades. On the medical side, the introduction of biologic therapy has significantly changed the characteristics of the patients undergoing surgery for Crohn's disease (CD), while its impact on the need for surgical intervention and the surgical outcomes of these patients is still debated. On the surgical side, the introduction of and the growing experience with minimally invasive approaches to IBD have had a significant impact on outcomes and quality of life in this patient population. During the past three decades the evidence has been accumulating in favor of a minimally invasive approach to CD. Clearly, this is probably one of the most challenging diseases to treat laparoscopically for the colorectal surgeon, especially when the disease is located in the colon and involves multiple segments.
过去二十年里，炎症性肠病（IBD）的外科和医学治疗方法有了显著的发展。在医学方面，生物治疗的引入显著改变了接受克罗恩病（CD）手术治疗的患者的特征，而其对手术干预需求和这些患者手术结果的影响仍存在争议。在外科方面，微创方法在 IBD 中的应用和经验的增长对该患者人群的结局和生活质量产生了重大影响。在过去三十年中，支持对 CD 采用微创方法的证据不断积累。显然，对于结直肠外科医生来说，这可能是腹腔镜治疗最具挑战性的疾病之一，尤其是当疾病位于结肠并涉及多个节段时。
